

**Supplementary Table 1.** Concept map of the search strategy

Criteria	Search
Population	(1) <i>De novo</i> (2) Kidney transplant (3) Renal transplant
Intervention	(1) mTOR inhibitor (2) Calcineurin inhibitor, mammalian target of rapamycin inhibitor (3) mTOR inhibitor, mTOR-I, rapamycin, everolimus (4) CNI (5) Cyclosporin, cyclosporine, Neoral, Sandimmune, CsA, tacrolimus, Prograf, FK506
Comparator	(1) MMF, mycophenolic acid (2) mycophenolate mofetil (3) CellCept (4) EC-MPS, enteric-coated mycophenolate sodium (5) Antiproliferative agent

mTOR, mammalian target of rapamycin; CNI, calcineurin inhibitor; CsA, cyclosporine; MMF, mycophenolate mofetil; MPS, mycophenolate sodium; EC-MPS, enteric coated mycophenolate sodium.

Supplementary Table 2. Search strategy for PubMed

Search number	Query	Sort by	Filters	Search details	Results	Time
1	((de novo) OR (kidney transplant)) OR (renal transplant)	Most recent	Randomized Controlled trial, adult: 19+ years	("de novo"[All Fields] OR ("kidney transplantation"[MeSH Terms] OR ("kidney"[All Fields] AND "transplantation"[All Fields]) OR "kidney transplant"[All Fields]) OR ("kidney"[All Fields] AND "transplant"[All Fields]) OR transplantation"[MeSH Terms] OR ("kidney"[All Fields] AND "transplantation"[All Fields]) OR "kidney transplantation"[All Fields] OR ("renal"[All Fields] AND "transplant"[All Fields]) OR "renal transplant"[All Fields]) AND ((randomizedcontrolledtrial[Filter]) AND (adult[Filter]))	4,546	4:59:35
2	((((((((((((((Mtor inhibitor) OR (Calcineurin inhibitor) OR (mammalian target of rapamycin inhibitor) OR (mTOR inhibitor) OR (Everolimus) OR (CNI) OR (cyclosporin) OR (Neoral) OR (CsA) OR (Prograf)) OR (FK506)	Most recent	Randomized controlled trial, adult: 19+ years	("mtor inhibitors"[Pharmacological Action] OR "mtor inhibitors"[MeSH Terms] OR ("mtor"[All Fields] AND "inhibitors"[All Fields]) OR "inhibitor"[All Fields] OR "mtor inhibitor"[All Fields] OR ("calcineurin inhibitors"[Pharmacological Action] OR "calcineurin inhibitors"[MeSH Terms] OR ("calcineurin"[All Fields] AND "inhibitors"[All Fields]) OR "calcineurin inhibitor"[All Fields] OR ("tor serine threonine kinases"[MeSH Terms] OR ("tor"[All Fields] AND "serine threonine"[All Fields] AND "kinases"[All Fields]) OR "tor serine threonine kinases"[All Fields] OR ("mammalian"[All Fields] AND "target"[All Fields] AND "rapamycin"[All Fields]) OR "mammalian target of rapamycin"[All Fields] AND ("antagonists and inhibitors"[MeSH Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields] OR "inhibitor s"[All Fields])) OR ("mtor inhibitors"[Pharmacological Action] OR "mtor inhibitors"[MeSH Terms] OR ("mtor"[All Fields] AND "inhibitors"[All Fields]) OR "mtor inhibitors"[All Fields] OR ("mtor"[All Fields] AND "inhibitor"[All Fields]) OR "rapamycin s"[All Fields] OR "rapamycin"[All Fields] OR "mTOR"[All Fields] OR ("rapamycin s"[All Fields] OR "sirolimus"[All Fields] OR "rapamycins"[All Fields] OR "sirolimus"[MeSH Terms] OR "everolimus"[All Fields]) OR "rapamycin"[All Fields] OR ("everolimus"[MeSH Terms] OR "everolimus"[All Fields]) OR "CNI"[All Fields] OR ("cyclosporine"[MeSH Terms] OR "cyclosporine"[All Fields]) OR "ciclosporin"[All Fields] OR "cyclosporin"[All Fields] OR "cyclosporin"[All Fields] OR "cyclosporine s"[All Fields] OR "cyclosporines"[All Fields]) OR ("cyclosporine"[MeSH Terms] OR "cyclosporine"[All Fields]) OR "ciclosporin"[All Fields] OR "ciclosporin"[All Fields] OR "ciclosporin"[All Fields] OR "ciclosporine s"[All Fields] OR "cyclosporines"[All Fields]) OR "sandimmun"[All Fields] OR "sandimmune"[All Fields] OR "cyclosporine s"[All Fields] OR "cyclosporines"[MeSH Terms] OR "cyclosporins"[All Fields] OR "cyclosporines"[All Fields]) OR ("tacrolimus"[MeSH Terms] OR "tacrolimus"[All Fields]) OR ("tacrolimus"[MeSH Terms] OR "tacrolimus"[All Fields]) OR ("tacrolimus"[MeSH Terms] OR "tacrolimus"[All Fields]) OR "prograf"[All Fields]) OR ("tacrolimus"[MeSH Terms] OR "tacrolimus"[All Fields] OR "fk506"[All Fields]) AND ((randomizedcontrolledtrial[Filter]) AND (adult[Filter]))	4,657	5:01:43

Supplementary Table 2. Continued 1

Search number	Query	Sort by	Filters	Search details	Results	Time
3	(((((((mycophenolic acid) OR (MMF)) OR (MMA)) OR (mycophenolate mofetil)) OR (CellCept)) OR (EC-MPS)) OR (enteric-coated mycophenolate sodium)) OR (antiproliferative agent)	Most recent	Randomized controlled trial, adult: 19+ years	("mycophenolic acid"[MeSH Terms] OR ("mycophenolic"[All Fields] AND "acid"[All Fields]) OR 1,065 "mycophenolic acid"[All Fields] OR "MMF"[All Fields] OR "MMA"[All Fields] OR ("mycophenolic acid"[MeSH Terms] OR ("mycophenolic"[All Fields] AND "acid"[All Fields]) OR "mycophenolic acid"[All Fields] OR ("mycophenolate"[All Fields] AND "mofetil"[All Fields]) OR "mycophenolate mofetil"[All Fields] OR ("mycophenolic acid"[MeSH Terms] OR ("mycophenolic"[All Fields] OR AND "acid"[All Fields]) OR "mycophenolate mofetil"[All Fields] OR "cellcept"[All Fields] OR ("mycophenolate"[All Fields] AND "mofetil"[All Fields]) OR "mycophenolate mofetil"[All Fields]) OR "EC-MPS"[All Fields] OR ("enteric-coated"[All Fields] AND ("mycophenolic acid"[MeSH Terms] OR ("mycophenolic"[All Fields] AND "acid"[All Fields]) OR "mycophenolic acid"[All Fields] OR ("mycophenolate"[All Fields] AND "sodium"[All Fields]) OR "mycophenolate sodium"[All Fields]) OR ("antiproliferative"[All Fields] OR "antiproliferatives"[All Fields]) AND ("agent"[All Fields] OR "agents"[All Fields])) AND ((randomizedcontrolledtrial[Filter]) AND (alladult[Filter]))	1,065	5:02:44
4	#1 AND #2 AND #3	Most recent	Randomized controlled trial, adult: 19+ years	((("de novo"[All Fields] OR ("kidney transplantation"[MeSH Terms] OR ("kidney"[All Fields] 571 AND "transplantation"[All Fields]) OR "kidney transplantation"[All Fields] OR ("kidney"[All Fields] AND "transplant"[All Fields]) OR "kidney transplant"[All Fields]) OR ("kidney transplantation"[MeSH Terms] OR ("kidney"[All Fields] AND "transplantation"[All Fields]) OR "kidney transplantation"[All Fields] OR ("renal"[All Fields] AND "transplant"[All Fields]) OR "renal transplant"[All Fields])) AND ("randomized controlled trial"[Publication Type] AND "adult"[MeSH Terms]) AND (("mtor inhibitors"[Pharmacological Action] OR "mtor inhibitors"[MeSH Terms] OR ("mtor"[All Fields] AND "inhibitors"[All Fields]) OR "mtor inhibitors"[All Fields] OR ("mtor"[All Fields] AND "inhibitor"[All Fields]) OR "mtor inhibitor"[All Fields] OR ("calcineurin inhibitors"[Pharmacological Action] OR "calcineurin inhibitors"[MeSH Terms] OR ("calcineurin"[All Fields] AND "inhibitors"[All Fields]) OR "calcineurin inhibitors"[All Fields] OR ("calcineurin"[All Fields] AND "inhibitor"[All Fields]) OR "calcineurin inhibitor"[All Fields] OR ("tor serine threonine kinases"[MeSH Terms] OR ("tor"[All Fields] AND "serine threonine"[All Fields] AND "kinases"[All Fields]) OR "tor serine threonine kinases"[All Fields] OR ("mammalian target of rapamycin"[All Fields] AND "target"[All Fields] AND "rapamycin"[All Fields]) OR "mammalian target of rapamycin"[All Fields]) AND ("antagonists and inhibitors"[MeSH Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields] OR "inhibitor"[All Fields] OR "inhibitor s"[All Fields])) OR ("mtor inhibitors"[Pharmacological Action] OR "mtor inhibitors"[MeSH Terms] OR ("mtor"[All Fields] AND "inhibitors"[All Fields]) OR "mtor inhibitors"[All Fields] OR ("mtor"[All Fields] AND "inhibitor"[All Fields]) OR "mtor inhibitor"[All Fields]) OR "mTOR- i"[All Fields] OR ("rapamycin s"[All Fields] OR "rapamycine"[All Fields] OR "rapamycins"[All Fields] OR "sirolimus"[MeSH Terms] OR "sirolimus"[All Fields] OR "rapamycin"[All Fields]) OR ("everolimus"[MeSH Terms] OR "everolimus"[All Fields]) OR "cni"[All Fields] OR ("cyclosporine"[MeSH Terms] OR "cyclosporine"[All Fields] OR "ciclosporin"[All Fields] OR "ciclosporine"[All Fields] OR "cyclosporin"[All Fields] OR "cyclosporine s"[All Fields] OR "cyclosporins"[MeSH Terms] OR "cyclosporins"[All Fields] OR "cyclosporines"[All	571	5:03:37

Supplementary Table 2. Continued 2

Search number	Query	Sort by	Filters	Search Details	Results	Time
				Fields) OR ("cyclosporine"[MeSH Terms] OR "cyclosporine"[All Fields] OR "ciclosporin"[All Fields] OR "ciclosporine"[All Fields] OR "cyclosporin"[All Fields] OR "cyclosporine s"[All Fields] OR "cyclosporins"[MeSH Terms] OR "cyclosporins"[All Fields] OR "cyclosporines"[All Fields] OR "cyclosporine"[MeSH Terms] OR "cyclosporine"[All Fields] OR "ciclosporin"[All Fields] OR "cyclosporin"[All Fields] OR "neoral"[All Fields] OR "cyclosporin"[All Fields] OR "ciclosporine"[All Fields] OR "cyclosporin"[All Fields] OR "cyclosporin"[All Fields] OR "cyclosporin s"[All Fields] OR "cyclosporins"[MeSH Terms] OR "cyclosporins"[All Fields] OR "cyclosporine"[All Fields] OR "cyclosporin"[All Fields] OR "cyclosporine"[All Fields] OR "sandimmun"[All Fields] OR "sandimmune"[All Fields] OR "cyclosporine s"[All Fields] OR "cyclosporins"[MeSH Terms] OR "cyclosporins"[All Fields] OR "cyclosporines"[All Fields] OR "CsA"[All Fields] OR ("tacrolimus"[MeSH Terms] OR "tacrolimus"[All Fields] OR "tacrolimus"[MeSH Terms] OR "tacrolimus"[All Fields] OR "tacrolimus"[MeSH Terms] OR "tacrolimus"[All Fields] OR "prograf"[All Fields] OR ("tacrolimus"[MeSH Terms] OR "tacrolimus"[All Fields] OR "fk506"[All Fields]) AND ("randomized controlled trial"[Publication Type] AND "adult"[MeSH Terms])) AND (("mycophenolic acid"[MeSH Terms] OR ("mycophenolic"[All Fields] AND "acid"[All Fields]) OR "mycophenolic acid"[MeSH Terms] OR "MMF"[All Fields] OR "MMA"[All Fields] OR ("mycophenolic acid"[MeSH Terms] OR ("mycophenolic"[All Fields] AND "acid"[All Fields]) OR "mycophenolic acid"[All Fields] OR ("mycophenolate"[All Fields] AND "mofetil"[All Fields]) OR "mycophenolate mofetil"[All Fields] OR ("mycophenolic acid"[MeSH Terms] OR "mycophenolic"[All Fields] AND "acid"[All Fields] OR "mycophenolate"[All Fields] OR "mycophenolic acid"[All Fields] OR "celcept"[All Fields] OR "mycophenolate"[All Fields] AND "mofetil"[All Fields]) OR "mycophenolate mofetil"[All Fields] OR "EC-MPS"[All Fields] OR ("enteric-coated"[All Fields] AND ("mycophenolic acid"[MeSH Terms] OR "mycophenolic"[All Fields] AND "acid"[All Fields]) OR "mycophenolic acid"[All Fields] OR ("mycophenolate"[All Fields] AND "acid"[All Fields]) OR "mycophenolate sodium"[All Fields] OR ("mycophenolate"[All Fields] AND "sodium"[All Fields]) OR "mycophenolate sodium"[All Fields]) OR ("antiproliferative"[All Fields] OR "antiproliferatives"[All Fields] AND ("agent"[All Fields] OR "agents"[All Fields])) AND ("randomized controlled trial"[Publication Type] AND "adult"[MeSH Terms])) AND ((randomizedcontrolledtrial[Filter]) AND (alladult[Filter]))		

**Supplementary Table 3.** Search strategy for Cochrane

ID	Search	Hits
#1	(mammalian target of rapamycin inhibitor):ti,ab,kw OR (mTOR inhibitor):ti,ab,kw OR (mTOR-I):ti,ab,kw OR (rapamycin):ti,ab,kw OR (Rapamune):ti,ab,kw (Word variations have been searched)	2,185
#2	(everolimus):ti,ab,kw OR (sirolimus):ti,ab,kw OR (CNI):ti,ab,kw OR (ciclosporin):ti,ab,kw OR (cyclosporine):ti,ab,kw (Word variations have been searched)	13,763
#3	(Neoral):ti,ab,kw OR (Sandimmune):ti,ab,kw OR (CsA):ti,ab,kw OR (tacrolimus):ti,ab,kw OR (Prograf):ti,ab,kw (Word variations have been searched)	8,617
#4	#1 or #2 or #3	18,731
#5	(MPA):ti,ab,kw OR (mycophenolic acid):ti,ab,kw OR (MMF):ti,ab,kw OR (mycophenolate mofetil):ti,ab,kw OR (CellCept):ti,ab,kw (Word variations have been searched)	6,696
#6	(EC-MPS):ti,ab,kw OR (enteric-coated mycophenolate sodium):ti,ab,kw OR (antiproliferative agent):ti,ab,kw (Word variations have been searched)	698
#7	#5 or #6	7,108
#8	("kidney transplantation"):ti,ab,kw OR ("renal transplant recipient"):ti,ab,kw AND (de novo):ti,ab,kw AND (adult):ti,ab,kw (Word variations have been searched)	8,344
#9	(RCT):ti,ab,kw OR ("randomized control trial"):ti,ab,kw OR ("randomized clinical trial"):ti,ab,kw OR ("randomized controlled study"):ti,ab,kw OR ("randomized prospective studies"):ti,ab,kw (Word variations have been searched)	646,260
#10	#4 AND #7 AND #8 AND #9	665

Search name: TRANSPLANT META; Date run: 21/08/2022 05:54:19.

**Supplementary Table 4.** Characteristics of included studies

Study	Participant	Total	Donor source	Type of induction	Exposure		Comparator		Outcome	Follow-up
					Dose/target level	Age/sex (male)	Dose/target level	Age/sex (male)		
Tedesco-Silva et al. (2015) [19]	Low/moderate immunological risk adult recipients of first ABO-compatible renal transplants	288	Living/deceased	Basiliximab	EVR 1.5 mg 2x day+ TAC (3–5 ng/mL)	44.1/68 (male)	MPS 720 mg 2x day+ TAC (6–8 ng/mL)	44.8/68 (male)	CMV infection, biopsy-proven ABMR, mortality, eGFR by MDRD	1 yr
Vitko et al. (2005) [21]	<i>De novo</i> KT patients	588	Living/deceased	NA	EVR 1.5 mg/day, 3.0 mg/day+CSA (113 and 101 ng/mL)	NA	MMF 2 g/day+ CSA (135 ng/mL)	NA	Biopsy-proven ABMR, mortality, infection adverse events	1, 3 yr
Qazi et al. (2017) [15]	<i>De novo</i> KT patients	575	Living/deceased	Basiliximab/rATG	EVR 1.5 mg/day+ LTac (3–8 ng/mL)	NA	MMF 2 g/day+STac (4–7 vs. 8–2 ng/mL); mo 2: 3–6 vs. 7–10 ng/mL; mo 6: 2–5 vs. 5–8 ng/mL)	NA	Composite efficacy failure rate (tBPAR/graft loss/death/loss to follow-up)	1 yr
Pascual et al. (2018) [14]	<i>De novo</i> KT patients	2,037	Living/deceased	Basiliximab/rATG	EVR 1.5 mg, 3.0 mg (3–8 ng/mL)+TAC (<2 mo: 4–7 ng/mL; 3–6 mo: 2–5 ng/mL; >6 mo: 2–4 ng/mL) or CSA (100–150, 50–100, 25–50 ng/mL, respectively)	49.3/710	MPA (1.4 g/day or 2 g/day) +TAC (<2 mo: 8–12 ng/mL; 3–6 mo: 6–10 ng/mL; >6: 5–8 ng/mL) or CSA (200–300, 150–200, 100–200 ng/mL, respectively)	49.3/707	Binary composite of tBPAR or eGFR, 50 mL/min per 1.73 m <sup>2</sup> (MDRD), mortality, any infection/adverse events	1 yr
Narumi et al. (2019) [13]	<i>De novo</i> KT patients	24	Living	Basiliximab	EVR 1.5 mg/day (3–8 ng/mL) +CSA 3 mg/kg (<2 mo: 100–200 ng/mL; 2–4 mo: 75–150 ng/mL; 4–6 mo: 50–100 ng/mL; >6 mo: 25–50 ng/mL)	43.7/8	MMF 2 g/day+CSA 4 mg/kg 200–300 ng/mL ≤2 mo and 100–250 ng/mL >2 mo	35/5	Graft survival (biopsy), patient survival, DSA levels, eGFR (MDRD)	1 yr
Takahashi et al. (2013) [18]	<i>De novo</i> KT patients	122	Living/deceased	Basiliximab	EVR 1.5 mg/day (C0: 3 to 8 ng/mL)+LCSA (100–200 ng/mL and were lowered to 75–150 ng/mL starting at mo 2; then 50–100 ng/mL starting at mo 4; 25–50 ng/mL from mo 6 onwards)	42.5/46	MMF 2 g/day+SCSA (C0: 200 to 300 ng/mL; 2 mo onwards: 100 to 250 ng/mL)	38.6/37	BPAR, graft loss, death eGFR (MDRD), adverse events, CMV infection	1 yr
Sommerer et al. (2019) [16]	Previous and primary KT patients	1,019	Living/deceased	Basiliximab	EVR (3–8 ng/mL)/TAC, EVR (3–8 ng/mL)/CSA	51/205	MPA/TAC	51/103	eGFR, proteinuria, treatment failure (BPAR, graft loss, and death) and adverse events, any infections	1 yr
Lorber et al. (2005) [12]	<i>De novo</i> KT patients	583	Living/deceased	Basiliximab	EVR 1.5 mg, 3.0 mg+ CSA (50–75 ng/mL)	43.3/110	MMF 2 g/day+ CSA (50–75 ng/mL)	43.4/132	BPAR, graft loss, death, or loss to follow-up and safety (adverse events and infection)	6 mo, 1, 2, 3 yr

Supplementary Table 4. Continued

Study	Participant	Total	Donor source	Type of induction	Exposure		Comparator		Outcome	Follow-up
					Dose/target level	Age/sex (male)	Dose/target level	Age/sex (male)		
Hiramitsu et al. (2016) [10]	De novo KT patients	24	Living	Basiliximab	EVR 1.5 mg (3–8 ng/mL)+CSA 3 mg/kg (2 mo: 100–200 ng/mL; 2–4 mo: 75–150 ng/mL; 2–4 mo: 50–100 ng/mL; >6 mo 25–50 ng/mL)	44.5/5	MMF 2 g/day+CSA 4 mg/kg (≤2 mo: 200–300 ng/mL; >2 mo: 100–250 ng/mL)	35/5	Graft survival, proteinuria CMV infection, biopsy-proven rejection	6 mo, 1.5 yr
Cibrik et al. (2013) [8]	De novo KT patients	833	Living/deceased	Basiliximab	EVR (target 3–8 ng/mL), or (6–12 ng/mL)+LCSA (25–50 ng/mL)	45.3/368	MPA 1.44 g/day+ std CSA (100–250 ng/mL)	47.2/189	BPAR, death, graft loss, or loss to follow-up and infections	1 yr
Ciancio et al. (2016) [4]	De novo KT patients	30	Living	Dual induction: basiliximab and rATG steroid free	EVR target (3–8 ng/mL)+ TAC 5–8 ng/mL	49.9/12	MPS 1,440 mg/day+ TAC (5–8 ng/mL)	48.5/11	BPAR, biopsy-proven CAI, eGFR, infections	1 yr
Bertoni et al. (2011) [17]	KT patients	106	NA	NA	EVR (8–12 ng/mL)+ LCSA (250–300 ng/mL)	NA	MPS 1,440 g/day+ std CSA (C2 500–700 ng/mL)	NA	BPAR, delayed graft function, eGFR, proteinuria	3 mo, 1 yr
Taber et al. (2019) [17]	KT patients currently on TAC and MPA	61	Living/deceased	Basiliximab or rATG	EVR roughly 6 ng/mL+ TAC (3–4 ng/mL)	51.0/27	MPS 750 mg–1 g daily+ TAC (7–8 ng/mL)	51.6/22	Magnitude of interstitial fibrosis, BPAR rates, patient and graft survival, immunosuppression interruptions or discontinuations, infections and hospitalizations	3 mo, 1 yr
Traitanon et al. (2019) [20]	Primary non-sensitized KT patients	833	Living	Alemtuzumab, steroid free	EVR (3–8 ng/mL)+low dose TAC (<2 mo: 8–10 ng/mL; 2–6 mo: 6–8 ng/mL; >6 mo: 4–8 ng/mL)	48.3/13	MMF+std TAC (<2 mo: 4–7 ng/mL; 3–6 mo: 3–5 ng/mL; >6 mo: 2–5 ng/mL)	48.4/16	Subpopulation of T cells including regulatory T cells and other T cell subpopulations, infection, acute rejection, graft loss and death	3 mo, 1 yr
David-Neto et al. (2014) [9]	Elderly KT patients	36	NA	Single dose rATG+steroids	EVR (3–8 ng/mL)+ low dose TAC (2–4 ng/mL)	NA	MMF+std TAC (5–7 ng/mL)	NA	Acute rejection, death, eGFR, infection	178 day
Lim et al. (2017) [11]	De novo KT patients	95	Living/deceased	Basiliximab	EVR 1.5 mg, 3.0 mg+ reduced CSA	46.9/24	MPA+std CSA	50.7/20	Risk for skin cancer, eGFR, graft loss, acute rejection, death, any infections	1 mo, 2 yr

EVR, everolimus; TAC, tacrolimus; MPS, mycophenolate sodium; CMV, cytomegalovirus; ABMR, antibody-mediated rejection; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease; KT, kidney transplant; NA, not applicable; CSA, cyclosporin A; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; LTac, low-dose tacrolimus; STac, standard-dose tacrolimus; tBPAR, treated biopsy-proven acute rejection; MPA, mycophenolic acid; DSA, donor-specific antibodies; LCSA, low-dose cyclosporin A; SCSA, standard dose cyclosporin A; std, steroid; CAI, chronic allograft injury.

**Supplementary Table 5.** Inclusion and exclusion criteria for study selection

Criteria	Detail
Inclusion criteria	
Population	Adult patients (>18 years old) with kidney transplant
Intervention	Maintenance immunosuppression with everolimus+CNI
Comparison	Maintenance immunosuppression with mycophenolate+CNI
Outcomes	Biopsy-proven acute rejection, graft function, mortality
Study design	Randomized controlled trials
Exclusion criteria	
Population	Combined organ transplant, ABO incompatibility, transplant of other organs such as heart, liver, etc.
Intervention and comparison	Other immunosuppression combination such as azathioprine+CNI, MMF+mycophenolate
Outcomes	Studies that did not assess the outcomes of interest
Study design	Studies other than randomized controlled trials, ongoing trials with no results

CNI, calcineurin inhibitor; MMF, mycophenolate mofetil.